MRNATE
Live / Applied — Fourth extension granted (statement of use) (as of 26 Jun 2025)
What this means for you
Not registered yet, but its 05 Apr 2022 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 97347635
- Mark type
- Stylized text
- Filed
- 05 Apr 2022
- Published for opposition
- 09 May 2023
- Attorney of record
- Nancy Sabarra
Goods and services
- Class 001 — Chemicals: Active biological ingredients for use in the manufacture of pharmaceuticals, namely, self-amplifying messenger RNA (sa-mRNA) encapsulated in a lipid nanoparticle composed of a cationic lipid and three helper lipids for use in the manufacture of pharmaceutical preparations containing messenger RNA (mRNA) for preventing and treating viruses and respiratory disorders; biochemicals for in vivo, ex vivo, on vivo or in vitro scientific research; biochemicals for medical research for use in the manufacture of pharmaceuticals for preventing and treating viruses and respiratory disorders; lipid nanoparticles for scientific, laboratory or medical research use
- Class 005 — Pharmaceuticals: Vaccines; vaccine adjuvants; medical, biological, and pharmaceutical preparations for medical use, namely, medical, biological and pharmaceutical preparations containing messenger RNA (mRNA) for preventing and treating viral diseases and respiratory disorders; mRNA-based therapeutics in the nature of therapeutic agents and therapeutic agents for use in vivo, ex vivo, or in situ for the prevention and treatment of viruses and respiratory disorders; lipid nanoparticles for use as drug delivery carriers sold as an integral component of pharmaceutical preparations for intracellular delivery of self-amplifying messenger RNA (sa-mRNA) for preventing and treating viral diseases all for pharmaceutical, medical or medical diagnostic purposes; drug carriers for medical use, namely, drug delivery agents consisting of lipid nanoparticles that facilitate delivery of a wide range of pharmaceuticals; lipid nanoparticles for use as drug delivery carriers sold as an integral component of pharmaceutical preparations; pharmaceutical preparations, namely, messenger RNA (mRNA) therapeutic agents and delivery agents comprised of lipid nanoparticle carriers and polymers for the delivery of mRNA to human cells
- Class 042 — Scientific and technological services: Pharmaceutical research and development; medical research services; biotechnology research; scientific research for medical purposes; design and development of medical technology; design, engineering, research, and development services in the field of nucleic acid sciences for medical and scientific applications; providing medical and scientific research in the fields of pharmaceuticals and vaccines
- Class 044 — Medical, beauty and agricultural services: Medical services; medical information; providing a website featuring medical information
Owner
- Seqirus Inc., Holly Springs, NC, US
- Seqirus Inc., Holly Springs, NC, US
Prosecution history
- 05 Jan 2026 — SOU TEAS EXTENSION RECEIVED
- 27 Jun 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 26 Jun 2025 — SOU EXTENSION 4 GRANTED
- 26 Jun 2025 — SOU EXTENSION 4 FILED
- 26 Jun 2025 — SOU TEAS EXTENSION RECEIVED
- 03 Mar 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 03 Jan 2025 — SOU EXTENSION 3 GRANTED
- 02 Jan 2025 — SOU EXTENSION 3 FILED
- 02 Jan 2025 — SOU TEAS EXTENSION RECEIVED
- 13 Jun 2024 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 06 Jun 2024 — SOU EXTENSION 2 GRANTED
- 06 Jun 2024 — SOU EXTENSION 2 FILED
- 06 Jun 2024 — SOU TEAS EXTENSION RECEIVED
- 21 Dec 2023 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 19 Dec 2023 — SOU EXTENSION 1 GRANTED